{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Neoplasms&page=4", "query": { "condition": "HER2 Negative Breast Neoplasms", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 683, "total_pages": 69, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Neoplasms&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Negative+Breast+Neoplasms&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T21:53:18.327Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01238133", "title": "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2010-12", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-09-04", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238133" }, { "nct_id": "NCT05879926", "title": "Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ovarian Function Suppression + Aromatase Inhibitor", "type": "DRUG" }, { "name": "Adjuvant Chemotherapy + Ovarian Function Suppression", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 3960, "start_date": "2023-10-18", "completion_date": "2034-07", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 1226, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05879926" }, { "nct_id": "NCT02102490", "title": "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 132, "start_date": "2014-06-10", "completion_date": "2018-10-22", "has_results": true, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 27, "location_summary": "Sedona, Arizona • Tucson, Arizona • San Francisco, California + 22 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02102490" }, { "nct_id": "NCT04060862", "title": "A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-11-21", "completion_date": "2023-08-29", "has_results": true, "last_update_posted_date": "2024-11-08", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Florham Park", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060862" }, { "nct_id": "NCT00636441", "title": "Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-Stage Breast Cancer" ], "interventions": [ { "name": "Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 56, "start_date": "2008-04", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2015-12-11", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00636441" }, { "nct_id": "NCT02315196", "title": "Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-negative Breast Cancer", "HER2-negative Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Triple-negative Breast Cancer" ], "interventions": [ { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 62, "start_date": "2015-02-25", "completion_date": "2041-07", "has_results": true, "last_update_posted_date": "2023-03-29", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315196" }, { "nct_id": "NCT05020860", "title": "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasm", "Breast Cancer Female", "Breast Cancer Invasive", "Breast Cancer Stage II", "Breast Cancer Stage III", "Triple Negative Breast Cancer", "Hormone Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Triple Negative Breast Neoplasms", "Estrogen Receptor-positive Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pertuzumab/Trastuzumab/Hyaluronidase-zzxf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Breast Care Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2023-04-18", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020860" }, { "nct_id": "NCT00866905", "title": "Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 168, "start_date": "2009-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 20, "location_summary": "Aventura, Florida • Fort Myers, Florida • Lakeland, Florida + 16 more", "locations": [ { "city": "Aventura", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866905" }, { "nct_id": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2020-12-17", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 9, "location_summary": "Commack, New York • Harrison, New York • New York, New York + 5 more", "locations": [ { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Uniondale", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04556773" }, { "nct_id": "NCT00934895", "title": "Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "abraxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 27, "start_date": "2009-07-15", "completion_date": "2015-08-12", "has_results": true, "last_update_posted_date": "2023-09-18", "last_synced_at": "2026-10-10T21:53:18.327Z", "location_count": 3, "location_summary": "Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey", "locations": [ { "city": "Camden", "state": "New Jersey" }, { "city": "Hamilton", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00934895" } ] }